Sorafenib-Induced Spiny Follicular Hyperkeratosis: A Case Report with Review of Literature

Abstract Sorafenib is a multikinase inhibitor used in the treatment of various solid tumors. Mucocutaneous adverse events are experienced by 70 to 90% patients receiving sorafenib, underscoring importance awareness among oncologists and dermatologists. Spiny follicular hyperkeratosis (SFH) benign rarely reported skin reaction linked sorafenib. It characterized flesh-colored or white, hyperkeratotic spicules, preferentially involving face, scalp, upper trunk, arms. Besides being acknowledged as paraneoplastic cutaneous manifestation multiple myeloma, SFH has also been few diseases drugs, other than However, precise etiopathogenesis remains be elucidated. We report an interesting case 14-year-old child, 1 week following initiation Trichodysplasia spinulosa, minute digitate hyperkeratosis, keratosis pilaris, filiform warts, pityriasis rubra pilaris morphologically similar conditions that were excluded clinicopathological correlation. A complete resolution rash sorafenib dose reduction further reinforced our diagnosis. Our patient developed hand-foot reaction, facial erythema, eruptive nevi during treatment. The regrowth curly hair chemotherapy-induced anagen effluvium was development case. this familiarize clinicians with rare entity.